Toripalimab (PDCD1/PD1/CD279) - Research Grade Biosimilar
Product Specifications
Background
Toripalimab is humanized monoclonal antibody targeted at programmed death receptor 1 (PD-1), used to treat patients with unresectable or metastatic melanoma who have failed previous systemic system therapy, and is intended for treatment Breast cancer, lymphoma, malignant melanoma, urogenital cancer and other types of solid tumors.
Immunogen
Humanized / PDCD1/PD1/CD279 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Cancer, Immunology
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Product Datasheet
https://www.prosci-inc.com/?datasheet_sku=10-923
Fragment
IgG4-kappa
NCBI Organism
Homo sapiens
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
